Cargando…
Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial
BACKGROUND: The Shexiang Baoxin Pill (MUSKARDIA) has been used for treating coronary artery disease (CAD) and angina for more than 30 years in China. Nevertheless, methodologically sound trials on the use of MUSKARDIA in CAD patients are scarce. The aim of the study is to determine the effects of MU...
Autores principales: | Ge, Jun-Bo, Fan, Wei-Hu, Zhou, Jing-Min, Shi, Hai-Ming, Ji, Fu-Sui, Wu, Yang, Zhao, Yu-Lan, Qian, Jun, Jin, Yuan-Zhe, Liu, Ying-Wu, Wang, Sheng-Huang, He, Sheng-Hu, Yang, Ping, Wu, Jie, Lu, Feng, Hou, Zi-Shan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817287/ https://www.ncbi.nlm.nih.gov/pubmed/33273369 http://dx.doi.org/10.1097/CM9.0000000000001257 |
Ejemplares similares
-
Shexiang Baoxin Pill (MUSKARDIA) reduces major adverse cardiovascular events in women with stable coronary artery disease: A subgroup analysis of a phase IV randomized clinical trial
por: Shi, Haiming, et al.
Publicado: (2022) -
Effectiveness and safety of Shexiang Baoxin Pill (MUSKARDIA) in patients with stable coronary artery disease and concomitant diabetes mellitus: a subgroup analysis of a randomized clinical trial
por: Zhou, Jingmin, et al.
Publicado: (2023) -
A network-based method for mechanistic investigation of Shexiang Baoxin Pill’s treatment of cardiovascular diseases
por: Fang, Hai-Yang, et al.
Publicado: (2017) -
Protective Effect of Shexiang Baoxin Pill on Myocardial Ischemia/Reperfusion Injury in Patients With STEMI
por: Qin, Haixia, et al.
Publicado: (2021) -
Meta-analysis and trial sequential analysis of shexiang baoxin pill for coronary slow flow
por: Guo, Hongxin, et al.
Publicado: (2022)